

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

2025 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “RemeGen Co., Ltd. 2025 Third Quarterly Report” published by RemeGen Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2025 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board of directors of the Company (the “**Board**”) reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2025 Third Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, PRC
October 30, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

* For identification purpose only

Stock Code: 688331

Ticker Symbol: RemeGen

RemeGen Co., Ltd.*

2025 THIRD QUARTERLY REPORT

The board of directors and all directors of the Company undertake that there are no false representations or misleading statements contained in, or material omissions from, this announcement, and accept responsibilities for the truthfulness, accuracy and completeness of its contents in accordance with the applicable laws.

IMPORTANT NOTICE:

The board of directors, directors and senior management of the Company undertake that the content of the quarterly report is true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The Company's legal representative, person in charge of accounting function and person in charge of the accounting department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report.

Whether the third quarterly financial statements have been audited

☐ Yes ☒ No

I. KEY FINANCIAL INFORMATION

(i) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Item	The Reporting Period	Increase/decrease compared with the same period of the previous year (%)	From the beginning of the year to the end of the Reporting Period	Increase/decrease compared with the same period of the previous year (%)
Operating revenue	621,879,591.47	33.13	1,719,833,029.78	42.27
Total profit	-101,131,912.31	N/A	-550,700,575.38	N/A
Net profit attributable to shareholders of the listed company	-101,131,912.31	N/A	-550,700,575.38	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	-99,726,700.01	N/A	-545,244,239.68	N/A
Net cash flows from operating activities	N/A	N/A	217,057,433.94	N/A
Basic earnings per share (RMB/share)	-0.18	N/A	-1.01	N/A
Diluted earnings per share (RMB/share)	-0.18	N/A	-1.01	N/A
Weighted average return on equity (%)	-3.04	An increase of 8.26 percentage points	-26.70	An increase of 10.22 percentage points
Total R&D spending	243,367,673.06	-29.90	890,583,907.36	-22.79
R&D spending as a percentage of operating revenue (%)	39.13	A decrease of 43.63 percentage points	51.78	A decrease of 35.19 percentage points
	As at the end of the Reporting Period	As at the end of the previous year		Increase/decrease compared with the end of the previous year (%)
Total assets	5,977,129,884.12	5,498,518,168.82		8.70
Owners' equity attributable to shareholders of the listed company	2,320,083,063.64	1,986,200,620.94		16.81

Note: "The Reporting Period" means the three-month period from the beginning of the quarter to the end of the quarter, the same hereinafter.

(ii) Non-recurring items and amounts

√Applicable □ Not Applicable

Unit: RMB Currency: Renminbi

Non-recurring items	Current amount	Amount from the beginning of the year to the end of the Reporting Period	Description
Gains or losses on disposal of non-current assets, including the write-off of the asset impairment provisions	-57,730.47	152,937.44	Net gains or losses on disposal of non-current assets
Government grants recognised as current gains and losses, except those that are closely related to the Company's ordinary course of business operations, comply with national policies, granted based on determined standards, and have a lasting impact on the Company's profits and losses	2,346,324.54	5,869,377.03	Government grants recognised as other income
Gains and losses from changes in fair value arising from financial assets and financial liabilities held by non-financial enterprises and profits and losses from disposal of financial assets and financial liabilities other than effective hedging business related to the Company's ordinary course of business operations	1,238,226.39	1,900,018.06	Mainly due to gains from structured deposits
Other non-operating income and expenses other than the above items	-4,932,032.76	-13,378,668.23	Donation expenses in majority
Other gains and losses items classified to non-recurring gains and losses	-	-	
Less: Impact on income tax	-	-	
Impact on non-controlling interests (after tax)	-	-	
Total	-1,405,212.30	-5,456,335.70	

Explanations are required for defining items that are not set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recurring Gains and Losses as non-recurring items with significant amounts and for defining the non-recurring items that are set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recurring Gains and Losses as recurring items.

√Applicable ☐ Not Applicable

Unit: RMB Currency: Renminbi

Item	Amount involved	Reason
Additional value-added tax deductions	5,837,121.14	Tax incentives for business activities
Government grants related to long-term assets	7,439,117.42	Lasting impact on the Company's gains and losses

(iii) Changes in key accounting data and financial indicators and reasons for changes

√Applicable □ Not Applicable

Item	Percentage change (%)	Primary reason
Operating revenue_The Reporting Period	33.13	This was largely due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection.
Operating revenue From the beginning of the year to the end of the Reporting Period	42.27	
Total profit_The Reporting Period	N/A	This was largely due to a significant increase in product sales revenue, R&D pipeline optimization of the Company, a decrease in various R&D expenditures, and the Company's execution of a license agreement with Vor Biopharma Inc. for the paid-licensing of its proprietary telitacicept, granting Vor Biopharma Inc. the exclusive right to develop and commercialize telitacicept worldwide (excluding Greater China). This resulted in a reduction in overseas clinical trial expenses for telitacicept, consequently leading to a substantial decrease in losses for the year.
Total profit From the beginning of the year to the end of the Reporting Period	N/A	
Net profit attributable to shareholders of the listed company_The Reporting Period	N/A	
Net profit attributable to shareholders of the listed company From the beginning of the year to the end of the Reporting Period	N/A	
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses_The Reporting Period	N/A	
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses From the beginning of the year to the end of the Reporting Period	N/A	
Net cash flows from operating activities_From the beginning of the year to the end of the Reporting Period	N/A	This was largely due to new large-scale cash inflows from technology licensing during the year and an increase in cash received from the sale of goods and provision of services due to increased product sales, resulting in an increase in net cash flows from operating activities.

Basic earnings per share (RMB/share)_The Reporting Period	N/A	This was largely due to the reduction in net loss caused by the aforementioned reasons.
Basic earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period	N/A	
Diluted earnings per share (RMB/share)_The Reporting Period	N/A	
Diluted earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period	N/A	
Total R&D spending_The Reporting Period	-29.90	The Company optimized its R&D pipeline and various R&D expenditures decreased. Furthermore, the Company executed a license agreement with Vor Biopharma Inc. for the paid-licensing of its proprietary telitacicept, granting Vor Biopharma Inc. the exclusive right to develop and commercialize telitacicept worldwide (excluding Greater China). This resulted in a reduction in overseas clinical trial expenses for telitacicept.
Total R&D spending_From the beginning of the year to the end of the Reporting Period	-22.79	
R&D spending as a percentage of operating revenue (%)_The Reporting Period	A decrease of 43.63 percentage points	The decrease in the ratio of R&D spending to operating revenue was due to a significant increase in operating revenue on one hand and a reduction in R&D spending caused by the aforementioned reasons on the other hand.
R&D spending as a percentage of operating revenue (%)_From the beginning of the year to the end of the Reporting Period	A decrease of 35.19 percentage points	

II. SHAREHOLDER INFORMATION

(i) Total number of ordinary shareholders, number of preferred shareholders with restored voting rights, and shareholding of the top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	15,267			Total number of preferred shareholders with restored voting rights as at the end of the Reporting Period (if any)		-	
Shareholding of the top ten shareholders (excluding shares re-lent)							
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Number of restricted shares including shares re-lent	Shares pledged, marked or frozen	
						Share status	Quantity
HKSCC NOMINEES LIMITED	Unknown	208,569,228	37.01	0	0	Unknown	-
Yantai Rongda Venture Capital Center (Limited Partnership)	Domestic non-state-owned legal person	102,381,891	18.17	102,381,891	102,381,891	Nil	0
FANG JIANMIN	Overseas legal person	26,218,320	4.65	26,218,320	26,218,320	Nil	0
Yantai Rongqian Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	18,507,388	3.28	18,507,388	18,507,388	Nil	0
Yantai Rongyi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	16,630,337	2.95	16,630,337	16,630,337	Nil	0

I-Nova Limited	Overseas legal person	13,600,000	2.41	13,600,000	13,600,000	Nil	0
Yantai Rongshi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	9,190,203	1.63	9,190,203	9,190,203	Nil	0
Hong Kong Securities Clearing Company Limited	Overseas legal person	8,841,804	1.57	0	0	Nil	0
Bank of Communications Co., Ltd. – Wanjia Sector Selection Mixed Securities Investment Fund (LOF)	Others	7,000,000	1.24	0	0	Nil	0
RongChang Holding Group LTD.	Overseas legal person	4,111,338	0.73	4,111,338	4,111,338	Nil	0
Shareholding of the top ten holders of unrestricted shares (excluding shares re-lent)							
Name of shareholder	Number of unrestricted outstanding shares held	Share type and quantity		Share type	Quantity		
HKSCC NOMINEES LIMITED	208,569,228	Overseas listed foreign shares			208,569,228		
Hong Kong Securities Clearing Company Limited	8,841,804	RMB-denominated ordinary shares			8,841,804		
Bank of Communications Co., Ltd. – Wanjia Sector Selection Mixed Securities Investment Fund (LOF)	7,000,000	RMB-denominated ordinary shares			7,000,000		

China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund (中國建設銀行股份有限公司 – 工銀瑞信前沿醫療股票型證券投資基金)	4,000,000	RMB-denominated ordinary shares	4,000,000
Bank of China Limited – Guangfa Healthcare Securities Investment Fund (中國銀行股份有限公司 – 廣發醫療保健股票型證券投資基金)	3,987,466	RMB-denominated ordinary shares	3,987,466
China Construction Bank Corporation – Huitianfu Innovative Medicine Theme Hybrid Securities Investment Fund (中國建設銀行股份有限公司– 匯添富創新醫藥主題混合型證券投資基金)	2,620,698	RMB-denominated ordinary shares	2,620,698
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司 – 招商國證生物醫藥指數分級證券投資基金)	2,399,379	RMB-denominated ordinary shares	2,399,379
PAG Growth Prosperity Holding I (HK) Limited	2,235,782	RMB-denominated ordinary shares	2,235,782
China Minsheng Banking Corp., Ltd. - BOC Innovative Healthcare Hybrid Securities Investment Fund (中國民生銀行股份有限公司 – 中銀創新醫療混合型證券投資基金)	2,156,285	RMB-denominated ordinary shares	2,156,285
Beijing Lapam Healthcare Investment Centre (Limited Partnership) (北京龍磐健康醫療投資中心(有限合夥))	2,092,002	RMB-denominated ordinary shares	2,092,002

Description of the connected relationship or concerted actions among the above shareholders	Yantai Rongda Venture Capital Center (Limited Partnership), FANG JIANMIN, I-Nova Limited, and RongChang Holding Group LTD. had a relationship of acting in concert
Description of participation of top ten shareholders and top ten holders of unrestricted shares in margin trading and re-lending business (if any)	Nil

Note 1: The shares held by HKSCC NOMINEES LIMITED (香港中央結算(代理人)有限公司) are shares that it holds on behalf of several clients, and part of the H shares held by I-Nova Limited and RongChang Holding Group LTD. are registered under HKSCC NOMINEES LIMITED.

Note 2: As of the end of the Reporting Period, there were a total number of 15,248 Class A ordinary shareholders and 19 Class H ordinary shareholders, totalling 15,267 ordinary shareholders.

Participation of Shareholders with more than 5% shareholding, top ten shareholders and top ten holders of unrestricted outstanding shares in re-lending business

☐Applicable ☒ Not Applicable

Changes in top ten shareholders and top ten holders of unrestricted outstanding shares from the previous period attributable to re-lending/returning

☐Applicable ☒ Not Applicable

III. OTHER REMINDERS

Other important information about the operation of the Company during the Reporting Period that investors should be reminded of

☐Applicable ☒ Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(i) Types of audit opinions

☐Applicable ☒ Not Applicable

(ii) Financial statements

Consolidated Balance Sheet

September 30, 2025

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	September 30, 2025	December 31, 2024
Current assets:		
Cash and bank balances	1,070,277,163.56	762,492,395.54
Held-for-trading financial assets	109,343,391.25	-
Bills receivable	201,780,450.58	204,299,928.35
Accounts receivable	361,989,041.99	383,388,743.02
Receivables financing	66,649,661.83	11,097,822.85

Prepayments	199,387,966.97	241,373,752.00
Other receivables	50,495,704.79	24,283,132.94
Inventories	657,583,963.29	659,368,730.71
Other current assets	1,635,532.68	3,491,867.90
Total current assets	2,719,142,876.94	2,289,796,373.31
Non-current assets:		
Long-term equity investments	11,259,100.76	8,850,723.90
Investments in other equity instruments	119,152,359.03	59,313,437.97
Other non-current financial assets	11,537,475.88	4,037,475.88
Fixed assets	2,323,127,608.78	2,457,180,322.07
Construction in progress	535,489,814.61	283,231,455.78
Right-of-use assets	48,418,068.25	93,753,714.63
Intangible assets	154,667,578.99	143,131,261.71
Long-term deferred expenses	1,599,492.74	4,324,896.83
Other non-current assets	52,735,508.14	154,898,506.74
Total non-current assets	3,257,987,007.18	3,208,721,795.51
Total assets	5,977,129,884.12	5,498,518,168.82
Current liabilities:		
Short-term borrowings	1,071,410,580.80	1,083,853,548.13
Accounts payable	194,761,229.05	162,250,106.68
Contract liabilities	571,834,427.34	3,143,688.86
Payroll payable	213,004,511.36	209,986,022.76
Taxes payable	48,468,857.92	37,058,544.84
Other payables	320,588,843.38	314,995,392.79
Non-current liabilities due within one year	390,029,409.55	348,684,938.40
Other current liabilities	22,700,635.28	18,324,410.71
Total current liabilities	2,832,798,494.68	2,178,296,653.17
Non-current liabilities:		
Long-term borrowings	696,200,059.51	1,195,878,046.86
Lease liabilities	25,274,131.90	42,093,510.05
Deferred income	92,935,766.23	96,049,337.80
Deferred tax liabilities	9,838,368.16	-
Total non-current liabilities	824,248,325.80	1,334,020,894.71
Total liabilities	3,657,046,820.48	3,512,317,547.88
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	563,608,243.00	544,332,083.00
Capital reserve	6,923,757,144.60	6,290,989,900.90
Less: Treasury shares	262,382,928.10	445,329,702.16
Other comprehensive income	-32,327,629.91	-81,920,470.23
Retained earnings	-4,872,571,765.95	-4,321,871,190.57

Total equity attributable to owners (or shareholders) of the parent company	2,320,083,063.64	1,986,200,620.94
Total owners' equity (or shareholders' equity)	2,320,083,063.64	1,986,200,620.94
Total liabilities and owners' equity (or shareholders' equity)	5,977,129,884.12	5,498,518,168.82

The Company's legal
representative:
Wang Weidong

Person in charge of
accounting function:
Tong Shaojing

Person in charge of the
accounting department:
Wei Jianliang

Consolidated Statement of Income

January-September 2025

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2025 (January-September)	First three quarters of 2024 (January-September)
I. Total operating revenue	1,719,833,029.78	1,208,874,280.23
Including: Operating revenue	1,719,833,029.78	1,208,874,280.23
II. Total operating costs	2,268,418,316.44	2,316,244,667.13
Including: Operating costs	270,593,449.58	244,744,865.10
Taxes and surcharges	12,367,642.39	11,272,616.41
Selling expenses	822,658,892.95	622,700,750.52
Administrative expenses	215,621,316.70	234,621,471.72
R&D expenses	890,583,907.36	1,153,407,440.34
Finance costs	56,593,107.46	49,497,523.04
Including: Interest expenses	57,040,326.33	55,598,761.08
Interest income	3,570,684.25	8,544,332.69
Add: Other income	19,145,615.59	65,240,530.15
Gain from investment (loss denoted by "-")	-4,686,557.89	1,241,939.00
Including: Gain from investments in associates and joint ventures	408,376.86	-104,902.37
Gain on derecognition of financial assets measured at amortised cost	1,606,295.09	1,360,416.66
Gain from changes in fair value (loss denoted by "-")	293,722.97	718,287.12
Credit impairment loss (loss denoted by "-")	-3,632,557.18	-5,774,013.88
Asset impairment loss (loss denoted by "-")	-9,781.42	-10,006,510.93
Gain on disposal of assets (loss denoted by "-")	205,690.01	88,364.48
III. Operating profit (loss denoted by "-")	-537,269,154.58	-1,055,861,790.96
Add: Non-operating income	797,697.78	1,565,965.93

Less: Non-operating expenses	14,229,118.58	17,130,813.87
IV. Total profit (total loss denoted by “-”)	-550,700,575.38	-1,071,426,638.90
Less: Income tax expenses	-	-
V. Net profit (net loss denoted by “-”)	-550,700,575.38	-1,071,426,638.90
(i) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	-550,700,575.38	-1,071,426,638.90
(ii) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	-550,700,575.38	-1,071,426,638.90
VI. Other comprehensive income, net of tax	49,592,840.32	-42,366,321.69
(i) Other comprehensive income attributable to owners of the parent company, net of tax	49,592,840.32	-42,366,321.69
1. Other comprehensive income not to be reclassified to profit or loss	50,000,552.90	-38,099,566.59
(1) Changes in fair value of other equity instruments investments	50,000,552.90	-38,099,566.59
2. Other comprehensive income to be reclassified to profit or loss	-407,712.58	-4,266,755.10
(1) Translation differences of the financial statements in foreign currency	-407,712.58	-4,266,755.10
VII. Total comprehensive income	-501,107,735.06	-1,113,792,960.59
(i) Total comprehensive income attributable to owners of the parent company	-501,107,735.06	-1,113,792,960.59
VIII. Earnings per share:		
(i) Basic earnings per share (RMB/share)	-1.01	-1.99
(ii) Diluted earnings per share (RMB/share)	-1.01	-1.99

In case of a business combination under common control during the period, the net profit of the combined party which has been realised prior to the combination was RMB0, and the net profit of the combined party which has been realised in the previous period was RMB0.

The Company’s legal
representative:
Wang Weidong

Person in charge of
accounting function:
Tong Shaojing

Person in charge of the
accounting department:
Wei Jianliang

Consolidated Statement of Cash Flows

January-September 2025

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2025 (January-September)	First three quarters of 2024 (January-September)
I. Cash flows from operating activities:		
Cash receipts from sales of goods and provision of services	2,229,797,482.86	1,097,729,076.75
Tax refund received	3,199.68	14,112,207.51
Cash received from other operating activities	26,135,188.33	110,331,330.11
Sub-total of cash inflows from operating activities	2,255,935,870.87	1,222,172,614.37
Cash paid for goods and services	104,074,192.63	103,969,884.33
Cash paid to and on behalf of employees	776,054,088.56	837,884,001.41
Cash paid for taxes and levies	106,451,519.86	37,431,526.62
Cash paid for other operating activities	1,052,298,635.88	1,077,990,268.89
Sub-total of cash outflows from operating activities	2,038,878,436.93	2,057,275,681.25
Net cash flows from operating activities	217,057,433.94	-835,103,066.88
II. Cash flows from investment activities:		
Cash received from the disposal of investments	1,050,000,000.00	520,078,626.05
Cash received from investment income	1,606,295.09	1,360,416.66
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	1,610,219.63	5,461,797.61
Cash received from other investment activities	9,578,400.00	13,994,347.44
Sub-total of cash inflows from investment activities	1,062,794,914.72	540,895,187.76
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	175,212,674.86	179,951,645.19
Cash paid for investments	1,167,127,956.20	786,750,000.00
Sub-total of cash outflows from investment activities	1,342,340,631.06	966,701,645.19
Net cash flows from investing activities	-279,545,716.34	-425,806,457.43

III. Cash flows from financing activities:		
Cash received from capital contributions	783,623,475.65	1,032,897.91
Cash received from borrowings	1,333,647,815.42	1,315,592,447.57
Sub-total of cash inflows from financing activities	2,117,271,291.07	1,316,625,345.48
Cash paid for repayment of debts	1,630,099,036.42	1,569,400.00
Cash paid for distribution of dividends or profits or settlement of interest	66,397,042.91	53,218,519.45
Cash paid for other financing activities	49,806,464.41	59,778,979.19
Sub-total of cash outflows from financing activities	1,746,302,543.74	114,566,898.64
Net cash flows from financing activities	370,968,747.33	1,202,058,446.84
IV. Effects of changes in exchange rate on cash and cash equivalents	-620,373.83	-5,694,629.93
V. Net increase in cash and cash equivalents	307,860,091.10	-64,545,707.40
Add: Balance of cash and cash equivalents at the beginning of the period	759,530,043.42	726,551,931.36
VI. Balance of cash and cash equivalents at the end of the period	1,067,390,134.52	662,006,223.96

The Company's legal
representative:
Wang Weidong

Person in charge of
accounting function:
Tong Shaojing

Person in charge of the
accounting department:
Wei Jianliang

Adjustment of the financial statements for the beginning of 2025 when the Company implements the new accounting standards or interpretations for the first time

☐Applicable ☒Not Applicable

This is hereby notified.

Board of directors of RemeGen Co., Ltd.*
October 30, 2025